Hematologic Malignancies Clinical Trial
Official title:
Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation
Background:
Allogenic hematopoietic cell transplantation (HCT) is a procedure in which a person gets stem
cells from a donor in order to treat their disease. Researchers want to collect samples from
people who have had or will have HCT. They will perform tests on the samples to study the
immune system and its response to infections and disease.
Objective:
To collect biological samples from people who have had or are planning to have HCT to treat
primary immunodeficiencies, blood cancers, or disorders of T-cell proliferation and/or
dysregulation.
Eligibility:
People age 8 years and older who have undergone or are planning to undergo HCT.
Design:
Participants will be screened with:
Medical history
Medical chart review
Physical exam
Blood tests.
Participants may give blood and urine samples.
Participants may have a skin biopsy.
Participants may undergo apheresis. For this, a needle will be placed into an arm vein to
take blood. A machine divides the whole blood into parts. The sample cells are taken out and
the rest of the blood is returned through a second needle in the other arm.
Participants may have a bone marrow aspiration and biopsy. For this, the hipbone will be
numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the
needle.
Participants may have a tumor or other abnormal tissue biopsy. For this, a tissue sample is
obtained using a needle and syringe. They will sign a separate consent form. They may have a
body scan or ultrasound to help locate the tumor during the biopsy.
Participation lasts for as long as participants choose to give samples.
Background:
- Allogenic Hematopoietic Cell Transplantation (HCT) is a potentially curative option for
some patients with primary immunodeficiencies (PID) and hematological cancers.
- HCT for PID looks to restore defects in cells of hematopoietic origin allowing for
eradication of protracted or recurrent viral infections.
- The curative potential of allogenic HCT for hematologic malignancies is mediated by the
allogeneic immune system through a graft-versus-tumor (GVT) effect.
- Characterization of the immunologic landscape in patients with successful eradication of
viral infections and hematologic malignancies following allogenic HCT requires further
investigation.
Objectives:
-To collect and bank blood, apheresis products, tumor, body fluids, and other biospecimens
from patients with allogenic HCT and perform immunological landscape studies.
Eligibility:
-Patients age greater than or equal to 8 years of age and have undergone or are planning to
undergo HCT.
Design:
- Up to 100 subjects will be enrolled.
- Patients may undergo sampling of blood, apheresis products, tumor, effusions, ascites,
urine, bone marrow, skin, mucosa, saliva, stool, sputum, spinal fluid, or other tissues
or fluids for banking and laboratory studies.
- No investigational or experimental therapy will be given as part of this protocol.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Not yet recruiting |
NCT06296368 -
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
|
N/A | |
| Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
| Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
| Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 |